The chondroprotective agent ITZ-1 inhibits interleukin-1β-induced matrix metalloproteinase-13 production and suppresses nitric oxide-induced chondrocyte death

Journal of Pharmacological Sciences

Volumn 110, Issue 2, 2009, Pages 201-211

  Kimura, Haruhide ^a,b   Yukitake, Hiroshi ^a   Suzuki, Hirobumi ^a   Tajima, Yasukazu ^a   Gomaibashi, Koyo ^a   Morimoto, Shinji ^a   Funabashi, Yasunori ^a   Yamada, Kiyofumi ^b,c   Takizawa, Masayuki ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cartilage degradation; Cell death; Chondrocyte; ITZ 1; Matrix metalloproteinase (MMP) 13

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CHONDROPROTECTIVE AGENT; COLLAGEN; COLLAGENASE 3; IMIDAZO[5,1 C]THIAZINE DERIVATIVE; INTERLEUKIN 1BETA; ITZ 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; NITRIC OXIDE; PROTEOGLYCAN; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARTILAGE CELL; CARTILAGE DEGENERATION; CELL DEATH; CONTROLLED STUDY; ENZYME INHIBITION; KNEE; MALE; NONHUMAN; NOSE CARTILAGE; RAT;

EID: 67649637307     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.09076FP     Document Type: Article

References (38)

1. Loeser RF. Molecular mechanisms of cartilage destruction: mechanics, inflammatory mediators, and aging collide. Arthritis Rheum. 2006;54:1357-1360.
2. Takaishi H, Kimura T, Dalal S, Okada Y, D'Armiento J. Joint diseases and matrix metalloproteinases: a role for MMP-13. Curr Pharm Biotechnol. 2008;9:47-54. (Pubitemid 351266969)
3. Ge Z, Hu Y, Heng BC, Yang Z, Ouyang H, Lee EH, et al. Osteoarthritis and therapy. Arthritis Rheum. 2006;55:493-500. (Pubitemid 43887035)
4. Hunter DJ, Felson DT. Osteoarthritis. Br Med J. 2006;332:639-642.
5. Aigner T, Sachse A, Gebhard PM, Roach HI. Osteoarthritis: pathobiology-targets and ways for therapeutic intervention. Adv Drug Delivery Rev. 2006;58:128-149.
6. Vincenti MP, Brinckerhoff CE. Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: integration of complex signaling pathways for the recruitment of gene-specific transcription factors. Arthritis Res. 2002;4:157-164. (Pubitemid 34460754)
7. Pettipher ER, Higgs GA, Henderson B. Interleukin 1 induces leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint. Proc Natl Acad Sci U S A. 1986;83:8749-8753. (Pubitemid 17194943)
8. van de Loo AAJ, van den Berg WB. Effects of murine recombinant interleukin 1 on synovial joints in mice: measurement of patellar cartilage metabolism and joint inflammation. Ann Rheum Dis. 1990;49:238-245. (Pubitemid 20140749)
9. Mix KS, Mengshol JA, Benbow U, Vincenti MP, Sporn MB, Brinckerhoff CE. A synthetic triterpenoid selectively inhibits the induction of matrix metalloproteinases 1 and 13 by inflammatory cytokines. Arthritis Rheum. 2001;44:1096-1104. (Pubitemid 32433615)
10. Ahmed S, Wang N, Lalonde M, Goldberg VM, Haqqi TM. Green tea polyphenol epigallocatechin-3-gallate (EGCG) differentially inhibits interleukin-1β- induced expression of matrix metalloproteinase-1 and -13 in human chondrocytes. J Pharmacol Exp Ther. 2004;308:767-773. (Pubitemid 38134242)
11. Ahmed S, Wang N, Hafeez BB, Cheruvu VK, Haqqi TM. Punica granatum L. extract inhibits IL-1β-induced expression of matrix metalloproteinases by inhibiting the activation of MAP kinases and NF-κB in human chondrocytes in vitro. J Nutr. 2005;135:2096-2102. (Pubitemid 41298371)
12. Aiger T, Kim HA, Roach HI. Apoptosis in osteoarthritis. Rheum Dis Clin N Am. 2004;30:639-653. (Pubitemid 38917006)
13. Kühn K, D'Lima DD, Hashimoto S, Lotz M. Cell death in cartilage. Osteoarthritis Cartilage. 2004;12:1-16. (Pubitemid 38111546)
14. Cawston TE, Ellis AJ, Humm G, Lean E, Ward D, Curry V. Interleukin-1 and oncostatin M in combination promote the release of collagen fragments from bovine nasal cartilage in culture. Biochem Biophys Res Commun. 1995;215:377-385.
15. Bottomley KM, Borkakoti N, Bradshaw D, Brown PA, Broadhurst MJ, Budd JM, et al. Inhibition of bovine nasal cartilage degradation by selective matrix metalloproteinase inhibitors. Biochem J. 1997;323:483-488. (Pubitemid 27183134)
16. Terauchi R, Takahashi KA, Arai Y, Ikeda T, Ohashi S, Imanishi J, et al. Hsp70 prevents nitric oxide-induced apoptosis in articular chondrocytes. Arthritis Rheum. 2003;48:1562-1568. (Pubitemid 36682364)
17. Farndale RW, Buttle DJ, Barrett AJ. Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochim Biophys Acta. 1986;883:173-177. (Pubitemid 16027978)
18. Karran EH, Young TJ, Markwell RE, Harper GP. In vivo model of cartilage degradation - effects of a matrix metalloproteinase inhibitior. Ann Rheum Dis. 1995;54:662-669.
19. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55-63. (Pubitemid 14203433)
20. Liacini A, Sylvester J, Li WQ, Zafarullah M. Inhibition of interleukin-1-stimulated MAP kinases, activating protein-1 (AP-1) and nuclear factor kappa B (NF-κB) transcription factors downregulates matrix metalloproteinase gene expression in articular chondrocytes. Matrix Biol. 2002;21:251-262. (Pubitemid 34497016)
21. Han Z, Boyle DL, Chang L, Bennett B, Karin M, Yang L, et al. c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest. 2001;108:73-81. (Pubitemid 32634924)
22. Presle N, Cipolletta C, Jouzeau JY, Abid A, Netter P, Terlain B. Cartilage protection by nitric oxide synthase inhibitors after intraarticular injection of interleukin-1β in rats. Arthritis Rheum. 1999;42:2094-2102. (Pubitemid 30263592)
23. Yasuhara R, Miyamoto Y, Akaike T, Akuta T, Nakamura M, Takami M, et al. Interleukin-1β induces death in chondrocyte-like ATDC5 cells through mitochondrial dysfunction and energy depletion in a reactive nitrogen and oxygen species-dependent manner. Biochem J. 2005;389:315-323. (Pubitemid 41021134)
24. Burrage PS, Mix KS, Brinckerhoff CE. Matrix metalloproteinases: role in arthritis. Front Biosci. 2006;11:529-543. (Pubitemid 43258162)
25. Mitchell PG, Magna HA, Reeves LM, Lopresti-Morrow LL, Yocum SA, Rosner PJ, et al. Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. J Clin Invest. 1996;97:761-768. (Pubitemid 26060542)
26. Neuhold LA, Killar L, Zhao W, Sung ML, Warner L, Kulik J, et al. Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in mice. J Clin Invest. 2001;107:35-44. (Pubitemid 32047412)
27. Loeser RF, Erickson EA, Long DL. Motogen-activated protein kinases as therapeutic targets in osteoarthritis. Curr Opin Rheumatol. 2008;20:581-586.
28. 2δ ligand, reduces the development of experimental osteoarthritis by inhibiting metalloproteinases and inducible nitric oxide synthase gene expression and synthesis in cartilage chondrocytes. Arthritis Rheum. 2005;52:488-500.
29. 2δ ligand of the voltage gated calcium channel, inhibits in vivo activation of the Erk1/2 pathway in osteoarthritic chondrocytes: a PKCα dependent effect. Ann Rheum Dis. 2006;65:573-580.
30. Pelletier JP, Fernandes JC, Brunet J, Moldovan F, Schrier D, Flory C, et al. In vivo selective inhibition of mitogen-activated protein kinase kinase 1/2 in rabbit experimental osteoarthritis is associated with a reduction in the development of structural changes. Arthritis Rheum. 2003;48:1582-1593.
31. Gabay O, Gosset M, Levy A, Salvat C, Sanchez C, Pigenet A, et al. Stress-induced signaling pathways in hyalin chondrocytes: inhibition by Avocado-Soybean Unsaponifiables (ASU). Osteoarthritis Cartilage. 2008;16:373-384. (Pubitemid 351309176)
32. Farrell AJ, Blake DR, Palmer RM, Moncada S. Increased concentrations of nitrite in synovial fluid and serum samples suggest increased nitric oxide synthesis in rheumatic diseases. Ann Rheum Dis. 1992;51:1219-1222.
33. Loeser RF, Carlson CS, Carlo MD, Cole A. Detection of nitrotyrosine in aging and osteoarthritic cartilage. Arthritis Rheum. 2002;46:2349-2357.
34. Lee SW, Song YS, Shin SH, Kim KT, Park YC, Park BS, et al. Cilostazol protects rat chondrocytes against nitric oxide-induced apoptosis in vitro and prevents cartilage destruction in a rat model of osteoarthritis. Arthritis Rheum. 2008;58:790-800.
35. Yoon JB, Kim SJ, Hwang SG, Chang S, Kang SS, Chun JS. Non-steroidal anti-inflammatory drugs inhibit nitric oxide-induced apoptosis and dedifferentiation of articular chondrocytes independent of cyclooxygenase activity. J Biol Chem. 2003;278:15319-15325. (Pubitemid 36799870)
36. Kim SJ, Ju JW, Oh CD, Yoon YM, Song WK, Kim JH, et al. ERK-1/2 and p38 kinases oppositely regulate nitric oxide-induced apoptosis of chondrocytes in association with p53, caspase-3, and differentiation status. J Biol Chem. 2002;277:1332-1339. (Pubitemid 34968887)
37. Kim SJ, Kim HG, Oh CD, Hwang SG, Song WK, Yoo YJ, et al. p38 kinase-dependent and -independent inhibition of protein kinase C ζ and -α regulates nitric oxide-induced apoptosis and dedifferentiation of articular chondrocytes. J Biol Chem. 2002;277:30375-30381.
38. Lokey RS. Forward chemical genetics: progress and obstacles on the path to a new pharmacopoeia. Curr Opin Chem Biol. 2003;7:91-96. (Pubitemid 36126498)